Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

PaperCitations, authors & open-access status

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 362 citations, 2019 year and closed oa status.

362
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Yi‐Long Wu
Author
Ying Cheng
Author
Lin Wu
Author
You Lü
Author
Journal of Thoracic Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account